CCR5 and neoplasm: Because cotreatment of the PNET tissues with vorinostat and maraviroc mitigated peripheral T cell recruitment toward the PNET tissues that was induced by vorinostat alone, our findings implicate that vorinostat enhances T cell recruitment via engagement of CCR5, which is most likely expressed on the tumor cells.